Abstract:
There is provided a method of determining whether a subject belongs to a first or a second group of subjects, wherein the risk of having or developing of a renal impairment is higher in the first group than in the second group, comprising the steps of: a) measuring an amount of fibulin 1 in a sample from the subject to obtain a sample value; b) comparing the sample value to a reference value; and if the sample value is higher than the reference value, c1) concluding that the subject belongs to the first group; and if the sample value is lower than the reference value, c2) concluding that the subject belongs to the second group, wherein the sample is an optionally modified sample derived from urine or blood, such as an optionally diluted serum or plasma sample. Associated means are also provided.
Abstract:
The invention relates to a cooling circuit (90) for a vehicle (100), particularly a commercial vehicle, wherein the cooling circuit (90) comprises a combustion engine (10), a retarder cooler (30) for cooling a retarder (32), an EGR cooler (40) for cooling an exhaust gas of the combustion engine (10), and a coolant cooler (20) which is coupled to the combustion engine (10) for cooling the combustion engine (10) by means of a coolant. The retarder cooler (30) is arranged permanently in series with the EGR cooler (40) in a fluid path (60) of the coolant forming a return line for the coolant from the combustion engine (10) to the coolant cooler (20).
Abstract:
A chuck (100, 200, 500) for holding a master electrode (107, 207) or a substrate (111, 211) during an ECPR process is provided. The chuck comprises an interaction surface (102, 201) onto which the master electrode (107, 207) or the substrate (111, 211) is arranged, and attaching means (105, 205) for clamping said master electrode (107, 207) or said substrate (111, 211) to said interaction surface (102, 201) such that said master electrode (107, 207) or said substrate (111, 211) is conforming to the shape of said interaction surface (102, 201). Further, a method for bringing a master electrode in contact with a substrate in an ECPR process is provided. The method comprises the steps of arranging a master electrode or a substrate on a chuck, arranging a substrate or a master electrode on a second chuck, aligning said master electrode and said substrate such that a front side of said master electrode is at a distance from and facing a front side of said substrate, and bringing the front side of the master electrode into contact with the front side of the substrate by decreasing said distance such that a centre of the master electrode contacts a centre of the substrate, and continuously decreasing said distance while also continuously decreasing said convex shape.
Abstract:
The present disclosure relates to a sliding door arrangement including a sliding door, a rail system, with a rail which guides a sliding motion of the door, and an attenuation and retraction device, which brakes the sliding motion of the door at a brake position in the vicinity of a door end position and retracts the door to the end position. The door has a wheel, which is arranged to run on the rail, a pin, slideably mounted on the door, which is arranged to interact with the attenuation and retraction device, and optionally a pin movement limiting device, which, at least in a mounting position, limits the movement of the pin such that it does not extend further from the door than does said wheel.
Abstract:
There is provided compounds of formula I, wherein Y, ring A, Da, Db, D2, D3, L1, Y1, L2, Y2, L3 and Y3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.
Abstract:
Electrical components, e.g., radiators, are made by a method comprising the steps of (1) providing a substrate, e.g., a polymeric film, having a first facial side that has a metal coating, e.g., copper, and a second facial side that does not have a metal coating; (2) applying an etchresist to the metal coating to define a trace; (3) etching from the substrate the metal coating not covered by the etch-resist; (4) removing the etch-resist from the metal coating; and (5) plating, e.g., electroless plating, the uncovered metal coating with a plating material comprising at least one of silver, gold, and nickel.
Abstract:
Electrical components, e.g., radiators, are made by a method comprising the steps of (1) providing a substrate, e.g., a polymeric film, having a first facial side that has a metal coating, e.g., copper, and a second facial side that does not have a metal coating; (2) applying an etchresist to the metal coating to define a trace; (3) etching from the substrate the metal coating not covered by the etch-resist; (4) removing the etch-resist from the metal coating; and (5) plating, e.g., electroless plating, the uncovered metal coating with a plating material comprising at least one of silver, gold, and nickel.
Abstract:
There is provided compounds of formula I, wherein Y, ring A, D a , D b , D 2 , D 3 , L 1 , Y 1 , L 2 , Y 2 , L 3 and Y 3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C 4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.
Abstract:
There is provided compounds of formula (I), wherein E 1 , E 2a , E 2b , E 2c , E 4 , D 1 , D 2 , D 3 , L 1 , Y 1 , L 2 and Y 2 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C 4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.
Abstract:
There is provided compounds of formula I, wherein ring R 1a to R 1c , R 2a to R 2e , and X have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of leukotriene C 4 synthase is desired and/or required, and particularly in the treatment of a respiratory disorder and/or inflammation.